News Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Mar 3, 2021
—HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9th— —Roth Conference at 10:00 am ET on March 15th— —Oppenheimer Healthcare Conference at 1:50 pm ET on March 17th—
-
Feb 12, 2021
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced that President and Chief Executive...
-
Feb 9, 2021
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved...
-
Jan 5, 2021
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced that President and Chief Executive...
-
Dec 7, 2020
--Retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate safety and activity profile are not impacted by baseline platelet count-- VANCOUVER, BC, Dec. 7, 2020 /CNW/ - Sierra Oncology,...
-
Dec 5, 2020
--Momelotinib demonstrates robust overall survival in both JAKi-naïve and patients previously treated with ruxolitinib-- VANCOUVER, BC, Dec. 5, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a...
-
Dec 1, 2020
--Sierra Chief Development Officer Barbara Klencke to be joined by renowned myelofibrosis experts Jean-Jacques Kiladjian, Ruben Mesa and Srdan Verstovsek-- VANCOUVER, BC, Dec. 1, 2020 /CNW/ -...
-
Nov 25, 2020
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address...
-
Nov 12, 2020
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address...
-
Nov 5, 2020
- Efficacy data for momelotinib in myelofibrosis patients by baseline platelet levels also to be presented - VANCOUVER, BC, Nov. 5, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage...